A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Investigator: Eleni Efstathiou, MD

Study Coordinator: Gabrielle Hayes

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT05288166

Phone: 734.419.948

Protocol Number: PRO00036219


The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
More to Explore